CME GroupCME -4.41%81 ROE % is 16.68% as of Mar. 2026, which is 69% above its 10-year median of 9.87. GuruFocus rates CME with a GF Score™ of 81/100 and a GF Value™ of $270.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 791 Capital Markets companies, CME Group ranks better than 75.09% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CME Group's annualized net income for the quarter that ended in Mar. 2026 was $4,617 Mil. CME Group's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $27,673 Mil. Therefore, CME Group's annualized ROE % for the quarter that ended in Mar. 2026 was 16.68%.
The historical rank and industry rank for CME Group's ROE % or its related term are showing as below:
CME'
s ROE % Range Over the Past 10 Years
Min: 7.5 Med: 9.87 Max: 19.01
Current: 15.44
During the past 13 years, CME Group's highest ROE % was 19.01%. The lowest was 7.50%. And the median was 9.87%.
CME's ROE % is ranked better than 75.09% of 791
companies
in the Capital Markets industry
Industry Median: 6
vs CME: 15.44
CME Group (NAS:CME) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CME Group ROE % Related Terms
CME Group ROE % Historical Data
* Premium members only.
The historical data trend for CME Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Financial Data & Stock Exchanges subindustry, CME Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group ROE % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's ROE % distribution charts can be found below:
* The bar in red indicates where CME Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
CME Group (CME) has a ROE % of 16.68% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CME Group and its competitors. This is 69% above median its historical median of 9.87. Over the past decade, CME Group's ROE % has ranged from 7.50 to 19.01. According to the industry distribution chart, CME Group ranks #197 out of 791 companies in the Capital Markets industry, placing it in the top 24.9%.
Is CME Group's ROE % too high?
CME Group's current ROE % of 16.68% is 69% above median its 10-year median of 9.87. Over the past 10 years, this metric has ranged from a low of 7.50 to a high of 19.01. The Capital Markets industry median ROE % is 6.00. CME Group's value of 16.68% is 178% above this industry median. Based on the distribution chart, CME Group ranks #197 out of 791 companies in the Capital Markets industry, which is in the top quartile — a strong position relative to peers. Overall, CME Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CME Group's ROE % compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #197 out of 791 companies for ROE %. This places CME Group in the top 25% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. CME Group's value of 16.68% is 178% above this benchmark. Historically, CME Group's own ROE % has ranged from 7.50 to 19.01 over the past decade. While the company's 10-year median is 9.87 vs. the industry median of 6.00, CME Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Capital Markets company?
The median ROE % among Capital Markets companies is 6.00, based on 791 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current ROE % of 16.68% is 178% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CME Group and its competitors. For the Capital Markets industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current ROE % is 16.68%, which is 69% above median its own 10-year median of 9.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Modestly Undervalued. The stock's GF Value™ is $270.89, compared to a current price of $231.58 — trading 14.5% below its estimated fair value. The current ROE % is 16.68%, which is 69% above median its 10-year median of 9.87 and 178% above the Capital Markets industry median of 6.00. CME Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CME Group (CME), the current ROE % is 16.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be undervalued.
The current stock price of $231.58 is trading 14.5% below its estimated GF Value™ of $270.89.
GuruFocus considers CME Group to be Modestly Undervalued.
Key valuation signals for CME:
ROE %: 16.68% (69% above median its 10-year median of 9.87)
GF Value™: $270.89 vs. price of $231.58 (14.5% below fair value)
Industry Position: 178% above the Capital Markets median (#197 of 791)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
81GF Score
Get the complete analysis for CME
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
